Efter gentagne behandlinger med Nonafact skal patienterne undersøges for, om de har dannet neutraliserende antistoffer (inhibitorer), der skal mængdebestemmes i Bethesda- enheder (BU) vha. passende biologiske undersøgelsesmetoder.
After repeated treatment with Nonafact, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.